The Government gave details about the next arrival of vaccines that will occur between this Thursday and Saturday. Find out who the Moderna vaccines that arrive in Colombia are for.
The Ministry of Health announced on Tuesday that the vaccines that arrive from the Moderna pharmaceutical company will be for specific prioritization. As revealed by the entity, these doses would serve to complete vaccination schedules for people over 50 with comorbidities.
In addition, in people under 50 years of age who have already received their first dose and who suffer from some comorbidity.
Find out who are the Moderna vaccines that arrive in Colombia
It is important to bear in mind that in the case of comorbidities, these must be verified within those contemplated by the National Vaccination Plan to be prioritized.
The director of promotion and prevention, Gerson Bermont, commented that this process will be carried out respecting the period of 28 days defined for this type of population.
In the event that over doses of this batch that will arrive in the country, it will be used for first doses in the populations that are defined by the Government.
Before the end of September Moderna promised to deliver 4,080,000 million doses. This allows the process of the National Vaccination Plan to continue as planned with this biological agent, according to Bermont.
Get to know the innovative vaccine that the Moderna pharmaceutical company enlists
The Moderna company announced Thursday that it has begun a program to develop a single-dose vaccine. This would combine a booster against Covid-19 with another against the flu.
“Today we announce the first step of our innovative respiratory vaccine program. For the development of a single-dose vaccine that combines a booster against covid-19 and a booster against influenza ”, Moderna assured.
It is worth mentioning that the company last week delivered the results of its clinical trials to evaluate the application of a third dose. These were presented to health and European authorities to obtain the proper authorization.
“We are pleased to have requested a conditional marketing authorization from the European Medicines Agency for our booster (vaccine) candidate at the 50 microgram dose level,” he said when applying for permission.
Additionally, Moderna CEO Stéphane Bancel commented that studies show that the 50 microgram booster dose showed high antibody responses against the Delta variant.
It is worth mentioning that last August, the FDA began recommending the third dose for patients with weakened immune systems. That is, for organ transplant patients, people with HIV or some cancer patients.
Authorities in the United States recently also announced booster doses for the general population that have received messenger RNA vaccines. This means that patients who received the Pfizer and Moderna vaccines will have a third one starting the week of September 20.
It is worth mentioning that in the North American country this third dose applies to people who have already had the two initial doses more than eight months ago.